biostudies-literatureUnknown207(6)Nowak DGerman Research FoundationHealth + Life Science Alliance Heidelberg MannheimDeutsche ForschungsgemeinschaftDr. Werner Jackstädt-StiftungBundesinstitut für RisikobewertungTorsten Haferlach Leukämiediagnostik StiftungDeutsche KrebshilfeForum Gesundheitsstandort Baden-WürttembergMedical Faculty Mannheim, Heidelberg UniversityBritish journal of haematology2558-2562https://www.ebi.ac.uk/biostudies/studies/S-EPMC12710189biostudies-literaturePrimary CD34<sup>+</sup> cells of patients with vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome are highly sensitive to targeted treatment with TAK-243.PMC1271018960‐0102‐01.P638‐12710524143/235/80937SFB 1709/1 2025—533056198SFB 1709/1 2025-533056198MWK32-7531-26/8/260-0102-01.P638-12710524BW 4-5400/136/170113953Klink TPalme IDarwich AMetzgeroth GKlar AHahn MOblander JSchmitt NBelzer ACRapp FGol MNowak DDemmerle MAbba MHofmann FWeimer NAltrock EStreuer ARiabov VHofmann WKSteiner LNowak VfalsePrimary CD34<sup>+</sup> cells of patients with vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome are highly sensitive to targeted treatment with TAK-243.2025-01-01T00:00:00Z2025 Dec2026-06-07T05:07:06.945Z2026-06-07T03:07:07.88ZS-EPMC127101894107769810.1111/bjh.70203